

This is a countywide group covering NHS Derby & Derbyshire Integrated Care Board, Derbyshire Community Health Service Foundation Trust, Derbyshire Healthcare Foundation Trust, University Hospital of Derby and Burton and Chesterfield Royal Hospital foundation trusts. It provides recommendations on the prescribing and commissioning of drugs  
See <http://www.derbyshiremedicinesmanagement.nhs.uk/home>

## Key Messages from January's JAPC meeting

[Gluten free food prescribing policy](#) - expiry date has been extended by 12 months to December 2023 with no other changes to the guidance. This extension allows for discussions within the ICB regarding Glossop transition to JUCD.

[Hypertension guidance](#) has been updated. No amendments to the current guidance as the pharmacological management is in line with current NICE guidance, which has simplified target BP levels.

### Emollient Formulary

Routine review of the existing Derbyshire primary care emollient formulary. Main change to the formulary is the substitution of cost-effective choice of Epimax Moisturising Cream replacing ZeroCream; removal of Oilatum Cream 1050ml pump dispenser due to discontinuation; note added to clarify when urea containing cream (Imuderm- contains urea 5%) may be suitable and warnings about the risk of severe and fatal burns have been extended to all paraffin-based emollients regardless of paraffin concentration.

### MHRA NOTICES

**Valproate:** reminder of current Pregnancy Prevention Programme requirements; information on new safety measures to be introduced in the coming months. Reminder to healthcare professionals of the risks in pregnancy and current Pregnancy Prevention Programme requirements:

- continue to follow the existing strict precautions, including that valproate should not be prescribed to female children or women of childbearing potential unless other treatments are ineffective or not tolerated and that any use of valproate in women of childbearing potential who cannot be treated with other medicines is in accordance with the Pregnancy Prevention Programme.
- The Commission on Human Medicines (CHM) has advised that there should be greater scrutiny of the way valproate is prescribed and that further risk minimisation measures are required – **in particular that 2 specialists** should independently consider and document that there is no other effective or tolerated treatment for patients (male or female) aged under 55 years

## Guideline Group key messages – traffic light amendments

**Cenobamate – RED.** Request for tertiary centres should be in line with host area prescribing committee's decision. Include for example see Sheffield [shared care protocol](#)

**Dapagliflozin – multiple classifications. Remove Grey-** [license extension] Use in adults and children aged  $\geq 10$  years for the treatment of insufficiently controlled type 2 diabetes mellitus. Entry for this indication as covered within type 2 diabetes guideline/ specialist service for children.

**Cannabis (Sativex) – GREEN consultant/specialist initiation.** There is a requirement to maintain patient registry ([link](#)). The consultant/specialist is responsible for registering the patient.

**Cyproterone – GREEN consultant/specialist recommendation.** For licensed indications in the management of patients with prostatic cancer. Require baseline & 6 months LFT for long-term use.

**Hepatitis B vaccine - dual classification. DNP** for travel vaccine (unless in combination with Hep A vaccine- see [primary care prescribing guide](#)); **RED** vaccination of at-risk renal patients

Dementia BPSD guideline - review date extension to March 2023. DHcFT have undertaken a review to confirm current guideline is relevant and safe, and a full update is anticipated in order to improve accessibility.

Specials guideline update- loperamide licensed liquid removed as discontinued; trazodone- '50mg/5ml strength added as cost effective'

Formulary Nutritional chapter/ osteoporosis guideline- Adcal D3 dissolve tabs replaces Calfovite D3 sachets, which have been discontinued.

NICE Summary of antimicrobial prescribing guidance – managing common infections updated in Dec 2022. Changes made to recommendations for acute sore throat and scarlet fever (GAS), linking to NHSE/UKHSA interim guidance for children.

Formulary Infections chapter updated to new link.

### Definitions:

**RED:** drugs are those where prescribing responsibility lies with a hospital consultant or a specialist.

**AMBER:** drugs are those that although usually initiated within a hospital setting, could appropriately become the responsibility of the GP, under a shared care agreement.

**GREEN\*:** drugs are regarded as suitable for primary care prescribing.

**GREY\*:** drugs are those that JAPC does not recommend for use, except in exceptional circumstances, due to lack of data on safety, effectiveness, and/or cost-effectiveness.

**Do Not Prescribe (DNP)\*:** drugs, treatments or medical devices are **not** recommended or commissioned\* (\*unless agreed through the individual funding request route)

**CONSULTANT/SPECIALIST INITIATION:** consultant/specialist issues the first prescription usually following a consultation because:

- a. The patient requires specialist assessment before starting treatment and/ or
- b. Specialist short term assessment of the response to the drug is necessary.

**GPs will be asked to continue prescribing when the patient is stable or predictably stable**

**CONSULTANT/SPECIALIST RECOMMENDATION:** consultant/specialist requests GPs prescribe initial and on-going prescriptions, but ensures:

- a. There is no immediate need for the treatment and is in line with discharge policies and
- b. The patient response to the treatment is predictable and safe

## Traffic light changes

Drug	Date considered	Decision	Details
<b>Trastuzumab deruxtecan</b>	Jan 23	<b>RED</b>	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after <b>1 or more</b> anti-HER2 treatments. NHSE commissioned
<b>Brexucabtagene autoleucel (Tecartus)</b>	Jan 23	<b>RED</b>	Treatment of adults aged $\geq 26$ years with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. NHSE commissioned
<b>Eptacog alfa (activated) (NovoSeven)</b>	Jan 23	<b>DNP</b>	Treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis. ICB commissioned
<b>Eladocagene exuparvovec (Upstaza)</b>	Jan 23	<b>RED</b>	Treatment of patients aged $\geq 18$ months with a clinical, molecular and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase deficiency with a severe phenotype. NHSE commissioned
<b>Maribavir (Livtency)</b>	Jan 23	<b>RED</b>	Treatment of cytomegalovirus infection and/or disease that are refractory (with or without resistance) to $\geq 1$ prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adults who have undergone a haematopoietic stem cell transplant or solid organ transplant. NHSE commissioned
<b>Nirsevimab (Beyfortus)</b>	Jan 23	<b>RED</b>	Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. NHSE commissioned
<b>Relugolix (Orgovyx)</b>	Jan 23	<b>DNP</b>	Treatment of adults with advanced hormone-sensitive prostate cancer.
<b>Teclistamab (Tecvayli)</b>	Jan 23	<b>RED</b>	Monotherapy for the treatment of adults with relapsed and refractory multiple myeloma, who have received $\geq 3$ prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. NHSE commissioned.
<b>Cemiplimab</b>	Jan 23	<b>DNP</b>	<b>NICE TA848</b> - Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)
<b>Cabozantinib</b>	Jan 23	<b>RED</b>	<b>NICE TA849</b> - Cabozantinib for previously treated advanced hepatocellular carcinoma
<b>Amivantamab</b>	Jan 23	<b>DNP</b>	<b>NICE TA850</b> - Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy. NHSE commissioned
<b>Pembrolizumab</b>	Jan 23	<b>RED</b>	<b>NICE TA851</b> - Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer. NHSE commissioned
<b>Trifluridine-tipiracil</b>	Jan 23	<b>RED</b>	<b>NICE TA852</b> - Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments. NHSE commissioned
<b>Avatrombopag</b>	Jan 23	<b>RED</b>	<b>NICE TA853</b> - Avatrombopag for treating primary chronic immune thrombocytopenia. ICB commissioned
<b>Esketamine</b>	Jan 23	<b>DNP</b>	<b>NICE TA854</b> - Esketamine nasal spray for treatment-resistant depression. ICB commissioned

### DERBYSHIRE MEDICINES MANAGEMENT, PRESCRIBING AND GUIDELINES WEBSITE

This website is the first port of call for information on local NHS decisions and guidance on medicines use. It includes local prescribing formularies, JAPC decisions, traffic lights, shared care guidelines, medicines guidelines, newsletters, controlled drug resources, and other medicines management resources. The site improves upon previous sites in several ways. It is faster, more reliable, has its own search engine, and it is easier to find information. Content is constantly being updated and you can sign up for e-mail alerts to keep you up to date.